Darolutamide in Combination with Leuprolide Acetate and Exemestane in Ovarian Granulosa Cell Tumor

What is the Purpose of this Study?

This study focuses on individuals who have recurrent, adult-type ovarian granulosa cell tumor and who have progressed on an aromatase inhibitor (letrozole, exemestane, anastrozole). The purpose of the study is to evaluate the effects of a drug called darolutamide in combination with the drugs leuprolide acetate and exemestane for the treatment of ovarian tumors. Darolutamide in combination with leuprolide acetate and exemestane may shrink cancer but may also cause side effects. Researchers aim to determine whether these drugs will shrink cancer. Darolutamide, leuprolide acetate, and exemestane have already been approved individually by the U.S. Food and Drug Administration (FDA) to treat other cancers, but the combination of drugs is not approved for the treatment of this type of ovarian cancer. All participants will receive the same treatment (darolutamide along with leuprolide acetate and exemestane).


Eligibility

Not Available


Where can I participate?

Cedars-Sinai Cancer at SOCC : Garrett Crook


What is the full name of this clinical trial?

NRG-GY033: A Phase II Study of Androgen Receptor Inhibition by Darolutamide in Combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor

Study Details
Disease Type/Condition

Ovary

Principal Investigator

Taylor, Kristin

Co-Investigators

Bobbie Jo Rimel

Age Group

Adult

Phase

II

IRB Number

STUDY00003309


How do I learn more about this study?
Name

Garrett Crook

Email
Garrett.Crook@cshs.org
Study Detail
Disease Type/Condition

Ovary

Principal Investigator

Taylor, Kristin

Age Group

Adult

Phase

II

IRB Number

NRG-GY033


Contact
Name

Garrett Crook

Email
Garrett.Crook@cshs.org